%0 Journal Article %A Eugenia O’Kelly %A Sophia Pirog %A James Ward %A P. John Clarkson %T Ability of Fabric Facemasks Materials to Filter Ultrafine Particles at Coughing Velocity %D 2020 %R 10.1101/2020.04.14.20065375 %J medRxiv %P 2020.04.14.20065375 %X Objectives We examined the ability of fabrics which might be used to create homemade face masks to filter out ultrafine (0.1μm and smaller in diameter) particles at the velocity of adult human coughing.Method Twenty commonly available fabrics and materials were evaluated for their ability to reduce air concentrations of ultrafine particles at a face velocity of 16.5 m/s. Further assessment was made on the filtration ability of select fabrics while damp and of fabric combinations which might be used to construct homemade masks.Results Single fabric layers blocked a range of ultrafine particles. When fabrics were layered, significantly more ultrafine particles were filtered. Nonwoven fusible interfacing significantly increased filtration.Conclusions The current coronavirus pandemic has left many communities without access N95 facemasks. Our findings suggest that face masks made from layered common fabric can help filter ultrafine particles and provide some protection for the wearer when commercial facemasks are unavailable.STRENGHTS AND LIMITATIONS OF THIS STUDYTested a large number of potential facemask materials, including materials currently in common use such as Lycra which have not been previously testedEvaluated filtration efficiency at coughing velocities, more closely mimicking use-case of masks worn for community protection than previous studiesAssess the data from prior published work and current study, creating a picture of Filtration Efficiency and the impact of velocityDid not discriminate between pathogenic and non-pathogenic particlesBreathing resistance was estimated based on qualitative feedbackCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThis research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData from this study is freely available under a CC-BY license on Cambridge University Apollo open data repository https://doi.org/10.17863/CAM.51390 %U https://www.medrxiv.org/content/medrxiv/early/2020/06/20/2020.04.14.20065375.full.pdf